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Abstract 
Objective: To report on the cost-effectiveness of the Exercise for Health trial, comparing an exercise 
intervention with usual care during and following treatment for women with breast cancer.  
Methods: Women with breast cancer were randomized to an eight-month exercise intervention (involving 
regular contact with an exercise physiologist over the phone, n=67, or home-delivered face-to-face, n=67) or 
usual care (n=60) group and were assessed pre-intervention (five weeks post-surgery), mid-intervention (six 
months post-surgery) and 10 weeks post-intervention (12 months post-surgery). The benefit measures were 
‘number of improvers’ in quality of life (QoL; FACT-B+4) and quality-adjusted life years (QALYs; EQ-5D-
3L). Data on provider, patient and government costs were used to consider two cost scenarios: 1) a service 
provider model and, 2) a private model.  
Results: There were 69 improvers in the intervention group compared with 21 in the usual care group (odds 
ratio 2.09, 95% CI: 1.08, 4.01, p=0.033). The incremental cost per improver was AU$2,282-$2,644. QALY gain 
for the intervention group versus the usual care group was 0.009, with incremental cost per QALY gain for 
model one and two being AU$105,231 and AU$90,842, respectively. However, sensitivity analyses indicate that 
incremental cost per QALY gained was volatile to EQ-5D-3L weights.  
Conclusions: Findings suggest that a pragmatic exercise intervention yields more women with markedly 
improved QoL after breast cancer than usual care and may be cost-effective.  The results are less certain in 
terms of incremental cost per QALYs, however this may be an inappropriate measure for reflecting exercise 
benefit for women with breast cancer.  
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Background 
Long-term sequelae of breast cancer treatment are common; 60-70% of breast cancer survivors live with chronic 
adverse treatment-related side effects, such as upper-body symptoms, lymphoedema and/or fatigue [1]. Younger 
women can experience premature menopause, bone density loss, infertility and associated distress [2]. With 
increasing numbers of women diagnosed with breast cancer each year, together with improving survival rates, 
the need to understand treatment-related concerns and to identify safe, effective, evidence-based strategies to 
alleviate these side effects and improve quality of life is important.  
 
International cancer organisations recommend cancer survivors to engage in regular physical activity, eat a 
healthy diet and aim to keep their weight within a healthy range [3, 4]. Regular, moderate-intensity exercise 
confers numerous quality of life benefits to women during and following breast cancer treatment [5-10]. 
Exercise may prevent common and debilitating treatment-related side effects (i.e., fatigue, lymphoedema and 
weight gain)[5, 11-14] and can improve compliance to adjuvant treatment [15]. Further, evidence from a meta-
analysis using data from high quality breast cancer cohort studies, as well as evidence from a recent randomized 
trial evaluating exercise during chemotherapy for breast cancer, demonstrate a relationship between exercise 
after diagnosis and improved overall and breast cancer-specific survival, and reduced risk of breast cancer 
recurrence [16-18]. Thus, the potential impact to individuals through the integration of exercise within standard 
breast cancer therapy is significant. Unfortunately, most women with breast cancer are insufficiently active 
(based on national, physical activity guidelines),[19-21] and exercise is not routinely prescribed as part of their 
care.  
 
We completed a pragmatic, randomized, controlled trial designed to evaluate the feasibility and effectiveness of 
an eight-month exercise intervention for women commencing six weeks post-surgery for breast cancer [22]. The 
trial, Exercise for Health (EfH), was delivered one-on-one by a trained exercise physiologist either home-
delivered face-to-face or over the telephone. The intervention, irrespective of mode of delivery, was found to be 
both feasible and effective in preventing declines in fitness and function and improving quality of life during 
treatment and in facilitating recovery post-treatment [23]. The face-to-face delivery mode reflects the traditional 
approach used by exercise physiologists in the prescription of exercise and, at least in some countries such as 
Australia, there already exists public and private health reimbursement for use of such allied health services via 
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this mode. The telephone-delivery mode reflects a modality with broad population reach and with the potential 
for scalability in partnership with cancer organisations offering support and information via telephonic services 
[24]. 
Expenditure on healthcare resources is increasingly scarce and therefore new interventions need to demonstrate 
acceptable patient benefits to justify the additional investment. Cost-effectiveness analysis is a useful method in 
which to weigh the costs and consequences of interventions against other options. Consequently, the purpose of 
this study was to report on the cost-effectiveness comparing the EfH exercise intervention with usual care for 
women with breast cancer through either face-to-face or telephone delivery modes. 
 
Methods 
The EfH trial (ACT RN: 012606000233527) was approved by the Human Research Ethics Committee at the 
Queensland University of Technology and at each of the four participating hospitals. Investigators obtained 
informed consent from each participant. 
 
Sample and Intervention Description 
The EfH intervention was a prospective, three-arm randomized controlled trial evaluating an eight-month 
exercise program for women after surgery for primary breast cancer. The study participants (n=194) were 
women who were newly diagnosed with breast cancer, and were recruited from four participating hospitals in 
Brisbane (Australia) between October 2006 and June 2008. Women were eligible for the study if they were aged 
between 20-69 years and resided within 30 kilometres (18.6 miles) of Brisbane central business district. The 
intervention was delivered through either face-to-face home delivery or by telephone over an eight-month 
period starting six weeks after breast surgery. The intervention involved 16 scheduled sessions by a trained and 
qualified exercise physiologist. The sessions were weekly to begin with and became less frequent (monthly) 
towards the end of the intervention period to promote ongoing patient-driven exercise beyond the study end. The 
overall goal was for women to be exercising at least four days per week for 45 minutes, including aerobic and 
resistance-based exercise. The usual care group received no regular or formal advice outside of their routine 
healthcare contacts during the post-surgical period of the study. Women were randomized into one of the three 
groups via a computer-generated unblocked sequence of random numbers. Full details of the trial methods, 
sample and intervention outcomes have been previously published [22, 23]. 
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Data Collection 
Data were collected at baseline (six weeks post-surgery), mid-intervention (six months post-surgery) and post-
intervention (12 months post-surgery). At baseline, data items included standard socio-demographics, cancer 
disease and treatments, and a range of physical tests performed by centrally-trained-to-study-protocol exercise 
physiologists blinded to group allocation. For the current analysis, the main outcomes were: number of women 
with improved quality of life; quality-adjusted life years (QALYs); and intervention costs. 
Previously, the EfH intervention has demonstrated significant patient benefits for quality of life, fitness and 
fatigue [23]. For the present analysis, the number of women who reported substantial improvements in quality 
of life was used as a clear indicator of benefit. The FACT-B+4 questionnaire is a multi-dimensional tool, 
designed to assess quality of life for women with breast cancer. Quality of life ‘improvers’ were those who 
reported a clinically important increase of ≥8 points [25] on the FACT-B+4 score (score range: 0-160) between 
baseline to 12 months post-surgery. As a secondary outcome, due to being generic and widely used in economic 
evaluations, QALYs were also considered. QALYs are a generic outcome which combine life years (or survival) 
and quality of life or health utility. We used the Australian algorithm [26] to obtain a EuroQol-5D (EQ-5D-3L) 
weight (range zero to one) and derived QALYs for each participant. In women with breast cancer, convergent 
validity, internal consistency and test-retest reliability for the EQ-5D-3L is r>0.49, alpha=0.71 and kappa=0.7, 
respectively [27]. 
The types of costs included in the analysis were taken from a broad perspective covering health providers, 
patients and government. Two cost scenarios were considered: 1) a service provider model, where the 
intervention could be implemented by a community organisation supporting people with cancer and where the 
exercise physiologist is an employee of the organisation and, 2) a private model, where exercise physiologists 
working privately could integrate the intervention into their routine practice. In the first scenario the costs of 
labour, intervention materials and resources are included as costs to the community organisation however in the 
second scenario the government payments to the private exercise physiologist includes the labour and all other 
provisions. Furthermore, the private exercise physiologist would already have these items for all other types of 
patients and by costing additional intervention resources and materials, this was considered double-counting. In 
the service provider model, costs were incurred by the provider and patients. Project records provided the 
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quantities and most monetary values for intervention resources in the service provider model. These included: 
exercise physiologist and administrative salaries, participant education booklets and supportive materials, a 
range of exercise measurement devices and hand weights, telephone expenses, office consumables and rental 
and marketing expenses. Patient out-of-pocket expenses were included for exercise-related costs and fees for the 
private exercise physiologist. In the private model, the costs were incurred by the Australian Government that 
subsidises services by private, accredited exercise physiologists through the Medicare Benefits Schedule [28]. 
The private model also included patient out-of-pocket expenses but excluded patient travel costs (due to the 
home-delivered intervention). In both scenarios, costs relating to the routine healthcare for breast cancer were 
omitted because these were not expected to differ across the intervention and control arms. No exercise injuries 
occurred in the trial. Although the face-to-face and telephone intervention modes were separated in the main 
trial, here they were pooled because intervention resources were virtually identical, with the exception of vehicle 
leasing in the service provider model. Vehicle leasing was estimated at current commercial rates which included 
financing, fuel and all servicing for a small car. Costs for the usual care group were minimal and included 
patient out-of-pocket expenses collected in the trial. 
 
Data Analyses 
An intention-to-treat approach was taken to assess differences in the outcomes across the trial arms. All baseline 
socio-demographic and medical characteristics were compared across the intervention and control arms using 
Chi-square tests for categorical data and Student’s t-tests for continuous data. Comparing across treatment arms, 
the minimal important difference for the EQ-5D-3L is in the range of 0.06-0.09 points [27]. Generalised 
estimating equations models were used to assess both time and treatment main and interaction effects. QALYs 
were calculated using all assessments of EQ-5D-3L and the area-under-the-curve method to produce a single 
QALY for each person over 12 months [29]. Intervention costs were tallied for all components of the respective 
cost scenarios. An equivalent annual cost was used for exercise equipment [29]. The key outcomes were 
combined into ratios of incremental cost per improver and incremental cost per QALY. These provide the 
relative cost and health benefits of the intervention versus usual care. Costs were presented in 2014 Australian 
dollars. 
 
One-way sensitivity analyses were undertaken for the calculated QALYs using the 95% confidence interval for 
each group and variation in car leasing costs, representing plausible low and high QALYs and cost scenarios. 
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Patient costs for exercise equipment in the intervention group were self-reported but were unknown for the usual 
care group. In the base case, it was assumed 50% of the intervention group costs would apply to the usual care 
group and this was tested at 25%, 75% and 100% in sensitivity analyses. As most costs in the service provider 
model were collected and valued with point estimates, we also assessed group costs at ±30% in a sensitivity 
analysis. Finally, a probabilistic sensitivity analysis was undertaken to assess the likelihood of the intervention 
being cost-effective. Here simulation methods were applied and variables for cost and QALYs were varied 
simultaneously. Variations in estimates were made using beta distributions for QALYs (using statistical means 
and standard deviations) and normal distributions for costs (based on means and estimated standard deviations: 
sd=mean/6). This analysis was performed in TreeAge Pro 2014 [30].To interpret the results, a ratio of 
AU$50,000 per QALY gain was used as an acceptable threshold for cost-effective health care in line with 
reimbursement decisions in Australia [31]. 
 
Results 
The intervention and usual care groups were similar with respect to their socio-demographic and clinical 
characteristics. Women had an average age of 52±8 years, were overweight (mean body mass index=26.6±5.2 
kg/m2), and 30% and 62% were classified as having stage I and II+ disease, respectively [22]. 
 
The number of improvers was 69 (57%) in the intervention group versus 21 (39%) in the usual care group; an 
intervention effect of 48 additional women exceeding clinically meaningful changes in their health-related 
quality of life (odds ratio 2.09, 95% CI: 1.08, 4.01, p=0.033). Table 1 presents the utility scores at baseline, and 
at 6- and 12-months post-surgery, as well as changes in scores over time. The interaction effect between time 
and group was statistically significant (p<0.05). Compared with the usual care group, the intervention group 
reported minimally relevant improvements in EQ-5D-3L weights from baseline to 12 months post-treatment 
(p<0.05). In contrast, weights for the usual care group remained relatively stable over time (Table 1).  The mean 
costs per patient for the intervention through a service provider model were $967, $838 for the private model 
and $20 for usual care (Table 2). The highest proportion of total costs in the service provider model was labour 
costs (78%) and vehicle leasing costs (5%). 
 
Compared with usual care, the intervention required an additional $947 to $818 (depending on service model) to 
produce 48 additional women with significant improvements to their quality of life or an incremental cost of 
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$2,282 to $2,644 per improver (Table 3). Using the secondary outcome of QALYs, the incremental QALY gain 
for the intervention group was minor at 0.009 (Table 3). Compared with usual care, the cost per QALY gain was 
$90,842 and $105,231 for the two service models (Table 3). In the sensitivity analyses, variation in costs 
changed the cost per improver between $1,756 and $3,777 (Table 4). If the intervention reduced the number of 
additional ‘improvers’ by 30% from 48 to 34, the incremental cost would be $3,261 to $3,777 per improver. 
Sensitivity analyses indicated that the incremental cost effectiveness ratios using QALYs gained were most 
sensitive when the EQ-5D-3L weights were varied within the 95% confidence limits. The results ranged from 
$16,685 per QALY gain to usual care being superior (i.e., less expensive and higher QALYs) (Table 4). Other 
variations in variables tested (e.g., leasing costs) produced negligible changes to the incremental cost 
effectiveness ratios. The likelihood of the service provider model being cost-effective was 44.4%, and 46.3% for 
the private model, at a willingness-to-pay threshold of AU$50,000 per QALY gain [31]. 
 
Discussion 
In terms of the numbers of women reporting clinically significant improvements in quality of life, the 
intervention, using either service model, may be cost-effective at approximately AU$2,400 per improver (or 
AU$300 per month). Notably, the total and mean intervention costs for either service model were low for an 8-
month intervention and up to 16 contact sessions per patient. However, the cost effectiveness of the intervention, 
for either service model, was more uncertain using QALYs gained as a secondary outcome. These latter findings 
showed high volatility to the EQ-5D-3L weights and the likelihood of being cost-effective was 44-46%. In this 
study, the EQ-5D-3L was not sensitive to capture the intervention effect and therefore QALYs were not entirely 
appropriate for this context. While QALYs are the preferred outcome in health economic evaluations, a number 
of reasons reduce their usefulness here. The intervention duration was not expected to extend participant 
survival during the trial period. The mean health utility weight for our participants (0.84) was similar to those 
reported for the Australian general population (0.83 [32] and 0.89 [26]). Therefore, detecting differences in 
QALYs was unrealistic in our sample. 
 
The EfH intervention was designed to provide women with the skills and confidence to continue their physical 
activity regimens beyond the trial. Although we do not demonstrate the ongoing sustainability of these potential 
benefits, at a cost of approximately AU$2,400 per improver, the intervention produced several health benefits to 
participants at costs significantly less than for surgical or radiotherapy services. With growing numbers of 
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women surviving breast cancer treatment, funding for programs and services in the survivorship phase of cancer 
care is equally important as services in the diagnostic and treatment phases, if benefits are potentially life-long. 
Further, it seems likely that cost-effectiveness of exercise programs would be influenced and improved by high 
throughput, which will be dependent on institutional commitment and clinician support.   
When health-related quality of life data were reviewed further, ceiling effects pre-intervention were observed for 
25% of the intervention group and 33% of the usual care group. Also of note is that the EfH sample was likely 
more active at baseline compared with the wider breast cancer population [22]. This is not unique to the EfH 
trial and has been previously identified as a limitation of the generalizability of findings from the majority of 
exercise intervention trials involving women with breast cancer [33]. Both factors (that is, high quality of life 
scores and being physically active at time of study commencement) may mean that the intervention and usual 
care group health utility weights were more similar than might otherwise be true. This would underestimate 
health utility weights in our cost-effectiveness findings and result in a higher incremental cost per QALY ratio. 
In addition, several important intervention benefits found in the intervention group, including improved fatigue 
and fitness,[23] may not be adequately incorporated within these cost-effectiveness analyses. For example, 
while the FACT-B+4 includes an item for fatigue, it is not a validated fatigue tool; fitness benefits observed 
were objectively measured.   
Three studies have reported on the cost-effectiveness of exercise interventions among women diagnosed with 
breast cancer,[34-36] and one for patients with lung cancer [37]. Similarly to our study, the previous cost-
effectiveness studies used both short-term patient outcomes and supplemented these with QALYs. Two of the 
breast cancer studies were based on randomized, controlled trials but the time horizons (12 months to five 
years), the types of interventions (one multimedia, on prescribed 12-week physical exercise), frequency of 
contacts with allied health professionals (no regular contact, once only) and the characteristics of the samples 
and costing components varied substantially. Unsurprisingly, there were mixed results with the 12-week 
physical exercise intervention found to be cost-effective, while the multimodal intervention was not.  Further, 
neither trial assessed the cost-effectiveness of an exercise intervention that is designed and implemented 
according to exercise guidelines endorsed by a major cancer organisation (including the American Cancer 
Society) or exercise science body, such as the American College of Sports Medicine.     
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Conclusion 
In summary, an exercise intervention for women after diagnosis of breast cancer may be cost-effective if society 
is willing to pay ~AU$300 per month for women with breast cancer to have markedly improved quality of life. 
As such, findings from this study, which evaluated an exercise intervention in the real-world setting may also be 
affordable and beneficial from a public health perspective. Exercise is fast becoming considered an evidence-
based adjuvant treatment for cancer and these findings highlight its potential affordability. 
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Table 1: Health utility weightsa at pre-intervention, mid-intervention and post-intervention 
Pre-intervention  Mid-intervention  (6 months post-surgery)  
Post-intervention  
(12 months post-
surgery) 
p-value 
time x group 
interaction 
∆ mid-pre scoresb ∆ post-pre scoresb 
Mean (95% CI) Mean (95% CI) Mean (95% CI) ∆ (95% CI) ∆ (95% CI) 
EQ-5D-3L 
 Intervention 
 Usual care 
0.79 
0.83 
(0.77, 0.82) 
(0.80, 0.87) 
0.83 
0.81 
(0.80, 0.86) 
(0.76, 0.87) 
0.86 
0.85 
(0.84, 0.89) 
(0.81, 0.89) 
 0.037
0.04 (0.01, 0.06) 
-0.02 (-0.07, 0.03) 
0.07c ,d (0.04, 0.10) 
0.02 (-0.03, 0.06) 
a EQ-5D-3L: EuroQol5D utility score with Australian weights applied (range 0 = worse health state to 1 = best health state); change over time or difference between groups of >0.06 units is clinically important (Source: 
Pickard et al., 2007).  
b ∆ mid-pre scores = change between baseline to six months post-surgery utility scores; ∆ post-pre scores = change between baseline to 12 months post-surgery utility scores
c  Clinically meaningful difference between groups compared to the usual-care group. 
d  Clinically meaningful change over time.  
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Table 2: Intervention resources and costs by intervention provider type (AU$ 2014) 
Service provider model Private model 
n 
Mean 
cost $ 
Total 
$ n 
Unit 
cost $ 
Total 
$ 
Patient costs 
Exercise clothing, equipment & other 134 40.46 5,422.00 134 40.46 5,422.00 
Fees for accredited exercise physiologist 0 0 0 134 9.30 1,246.20 
Sub-total  40.46 5,422.00 49.76 6,668.20 
Government costs1 
GP chronic disease management services, 
prerequisite2  0 0 0 134 258.55 34,645.70 
Exercise physiologist MBS fee – 10 visits3 0 0 0 134 529.50 70,953.00 
Sub-total 0 0 788.05 105,598.70 
Personnel
Exercise physiologists, 16 
hours/participant 134 758.53 101,643.34 
Administrative staff, 3.5 hours/week for 16 
weeks = 56 hours total 134 17.13 2,296.00 
Sub-total 775.67 103,939.34 0 0
Intervention Materials 
Educational workbook exercise tracker 
Case management folder, 1 per participant 134 9.40 1,259.60 
Sub-total 9.40 1,259.60 0 0
Resources and other 
Number 
purchased
Junsd Stopwatch  4 13.57 54.29 
First Aid Kit  4 96.87 387.48 
Resuscitation masks  4 25.07 100.27 
Spyhgo, classroom set  4 66.24 264.94 
Goniometer, Robinson Pocket  4 48.50 193.99 
Dynamometer, Advanced Hand  4 290.99 1,163.96 
Scale, Platform Medical  4 332.56 1,330.24 
Polar FS1  4 102.54 410.16 
Dumbbell hand weights x 5 sets 5 230.00 1,150.00 
n 5,055.35 
Sub-total Annual equivalent cost 134 13.85 1,856.37 0 0
Intervention delivery 
Marketing costs 134 37.31 5,000.00 
Office rental 134 38.80 5,199.00 
Phone charges - assumed mobile plan 
$110 per month x 8 months 134 6.57 880.00 
1 car lease for 8 months $349.90 / 
fortnight for 17.33 fortnights 134 45.25 6,063.77 
Sub-total 127.93 17,142.77 0 0
TOTAL AU Dollars 2014 $967.31 $126,620 $837.81 $112,267 
1. Under the service provider arrangement the exercise physiologist would not be additionally charging patients for services and there
would not be costs incurred by government.
2. Prerequisite items of 721 and 723 for GP services are necessary for referral to the exercise physiologist. 
3. Exercise physiologist under the chronic disease management MBS item 10953, maximum five sessions allowed each calendar year. Here 
10 sessions assumed to cross two calendar years.
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Table 3: Costs, Improvers, QALYs and incremental cost-effectiveness ratios (AU$ 2014) 
Costs Improvers1 QALYs ICER2 ICER3 
Mean Incr # Incr Mean Incr Improvers QALYs 
Intervention - Service  $967  $947 
69 48 0.846 0.009 
$2,644  $105,231 
Intervention - Private EP  $838  $818 $2,282  $90,842 
Usual care  $20  ref 21 ref 0.837 ref ref ref 
EP = exercise physiologist ICER = incremental cost-effectiveness ratio, Incr – incremental, QALYs = quality-adjusted life years 
1. Improvers – number of women who met clinically important improvements on the FACT-B+4 scores (≥8 points) from baseline to 12
months post-surgery. 
2. ICERs are calculated as the incremental total cost divided by the incremental improvers
3. ICERs are calculated as incremental mean cost divided by incremental mean QALYs
Table 4: Results of sensitivity analyses on incremental cost per effects (AU$ 2014) 
Private EP model Service provider model 
Improvers QALYs Improvers QALYs
Base case $2,282 $90,842 $2,644 $105,231 
QALY Low 95% CI (intervention group) 0.824 n/a UC dominates1 n/a UC dominates1 
QALY High 95% CI (intervention group) 0.863 n/a $26,374 n/a $30,551 
QALY Low 95% CI (UC group) 0.797 n/a $16,685 n/a $19,328 
QALY High 95% CI (UC group) 0.877 n/a UC dominates1 n/a UC dominates1 
Leasing small car AU$63.54 / fortnight n/a n/a $2,606 $103,733 
Leasing larger car AU$116.14 / fortnight n/a n/a $2,680 $106,656 
Provider model costs 30% higher AU$1257 n/a n/a $3,454 $137,475 
Provider model costs 30% lower AU$880 n/a n/a $1,834 $95,559 
UC group out of pockets 25% of intvn group $2,311 $91,966 $2,672 $106,355 
UC group out of pockets 75% of intvn group $2,254 $89,718 $2,616 $104,107 
UC group out of pockets 100% of intvn group $2,226 $88,594 $2,587 $102,983 
Incremental number of improvers – 30% higher $1,756 n/a $2,034 n/a 
Incremental number of improvers – 30% lower $3,261 n/a $3,777 n/a 
CI = confidence interval, EP = exercise physiologist, QALYs = quality-adjusted life years, UC = usual care group, intvn - intervention 
1. Dominates = lower cost and higher QALYs. QALY values in these sensitivity analyses are the post-intervention unmodelled 95% CI values.
